JCT (Janction) fluctuates 108% in 24 hours: Trading volume surges driven by resonance with Jasmy testnet integration
Bitget Pulse2026/03/23 03:36Volatility Overview
In the past 24 hours, JCT price rebounded from a low of $0.002493 to a high of $0.005186, currently at $0.004503, with a fluctuation amplitude of 108.0%. Trading volumes surged significantly to approximately $58.52 million (CoinGecko data) and $67.54 million (CoinMarketCap data), ranking among the top, indicating increased market activity.
Brief Analysis of Abnormal Movements
• Trading volume soared: Within 24 hours, trading volume surged from a low to nearly $60 million, driving the price to rebound over 100% from the low around $0.0025. Bitget monitoring showed volatility reached as high as 50.3% at one point.
• Jasmy testnet linkage event: On March 22, Jasmy's official account confirmed that Chain Testnet was successfully linked with Janction, and the transfer of Jasmy test tokens was completed. This collaborative update sparked speculative attention within the community.
Market Views and Outlook
Market sentiment is predominantly bullish, with frequent trading signals (such as long entries at $0.0026, targeting above $0.0032), reflecting optimism regarding Jasmy ecosystem collaboration potential. However, with abnormal sell volume at 2.9 times and frequent sharp decline alarms of -19%-28% recently, analysts warn of high risks and potential short-term corrections under low market cap conditions (around $52 million), recommending careful attention to the $0.0025 support level.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New Zealand Dollar gains ground to near 0.5700 as RBNZ rate hike bets rise
Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business
Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.
Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital
As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.
Japanese Yen holds near one-month top vs weak USD as traders await Fed, BoJ meetings
